Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03332836 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03332836 is a Phase 1 study that was terminated before completion, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 21 participants.
The verdict
NCT03332836, a Phase 1 study, was terminated before completion, sponsored by Hanmi Pharmaceutical Company Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 2 Diabetes Mellitus.
Interventions
- BIOLOGICAL HM12460A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2020-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03332836
The ClinicalTrials.gov registry entry for NCT03332836 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HM12460A is the first listed.
NCT03332836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03332836 about?
NCT03332836 is a clinical study titled "Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus". This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 2 Diabetes Mellitus.
What is the current status of trial NCT03332836?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-10-25. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT03332836?
The interventions under investigation include: HM12460A (BIOLOGICAL).
Who is sponsoring clinical trial NCT03332836?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.